Information on FHL3

Basic details

Name: Hemophagocytic Lymphohistiocytosis, familial, 3 | Acronym: FHL3
Alt. names: familial Hemophagocytic lymphohistiocytosis 3 | Munc13-4 deficiency

Gene: UNC13D | MOI: Autosomal recessive | Mechanism of action:

No. of cases in DB: 0 | First reported in: 2003

Last updated on: 2023-02-28 16:41:18 by

OMIM: 608898

Orphanet: -

MONDO: -

DOID: 0110923

ClinGen:

Description

A rare disorder characterized by immune dysregulation with hypercytokinemia, defective function of natural killer cell, and massive infiltration of several organs by activated lymphocytes and macrophages. The clinical features of the disease include fever, hepatosplenomegaly, cytopenia, and less frequently neurological abnormalities ranging from irritability and hypotonia to seizures, cranial nerve deficits and ataxia. FHL3 is caused by mutations in the UNC13D gene on chromosome 17q25.1.

Management

Early recognition may allow prompt treatment, as individuals frequently have fatal outcomes unless treated by control of infectious triggers and chemoimmunotherapy, followed by HSCT.

Please mind that full curation of this condition has not been completed yet. It is currently ongoing.

0 reported cases added to GenIA

SubjectID Sex Fam.ID AD AFM Validity Country Population Reference & Pub.code

AD: Age at genetic diagnosis; AFM: age at first manifestation; PMID: PubMed ID; GRID: GenIA reference ID (ref. not in PubMed).

Summary of clinical findings

[Considering only Definitive and Possible cases]

Rank Clinical term Present Absent Unreported
1 Reduced natural killer cell activityarrow icon 13 (99.9%) 0 (0.0%) 0 (0.0%)
2 Anemiaarrow icon 12 (85.7%) 0 (0.0%) 2 (14.3%)
3 Granulocytopeniaarrow icon 11 (78.6%) 0 (0.0%) 3 (21.4%)
4 Infantile onsetarrow icon 6 (40.0%) 0 (0.0%) 9 (60.0%)
5 Juvenile onsetarrow icon 5 (33.3%) 0 (0.0%) 10 (66.7%)
6 Neonatal onsetarrow icon 2 (13.3%) 0 (0.0%) 13 (86.7%)
7 Childhood onsetarrow icon 1 (6.7%) 0 (0.0%) 14 (93.3%)
8 Early young adult onsetarrow icon 1 (6.7%) 0 (0.0%) 14 (93.3%)

Please mind that full curation of this condition has not been completed yet. It is currently ongoing.

Summary of treatment outcomes

[Considering only Definitive and Possible cases]

Treatment ⓘ Responses & clinical indications

Please mind that full curation of this condition has not been completed yet. It is currently ongoing.